The production and immunogenicity of human papillomavirus type 58 virus-like particles produced in Saccharomyces cerevisiae

Journal of Microbiology

Volumn 50, Issue 5, 2012, Pages 813-820

  Kwag, Hye Lim ^a   Kim, Hyoung Jin ^a   Chang, Don Yong ^a   Kim, Hong Jin ^a  

^a Chung Ang University   (South Korea)

Author keywords

human papillomavirus; immunogenicity; Saccharomyces cerevisiae; vaccine; virus like particle

Indexed keywords

EID: 84868529201     PISSN: 12258873     EISSN: 19763794     Source Type: Journal    
DOI: 10.1007/s12275-012-2292-1     Document Type: Article

References (37)

1. Bao, Y. P., Li, N., Smith, J. S., and Qiao, Y. L. 2008. Human papillomavirus type distribution in women from Asia: a meta-analysis. Int. J. Gynecol. Cancer18, 71-79.
2. Bishop, B., Dasgupta, J., Klein, M., Garcea, R. L., Christensen, N. D., Zhao, R., and Chen, X. S. 2007. Crystal structures of four types of human papillomavirus L1 capsid proteins: understanding the specificity of neutralizing monoclonal antibodies. J. Biol. Chem. 282, 31803-31811.
3. Bosch, F. X., Lorincz, A., Munoz, N., Meijer, C. J., and Shah, K. V. 2002. The causal relation between human papillomavirus and cervical cancer. J. Clin. Pathol. 55, 244-265.
4. Buck, C. B., Thompson, C. D., Pang, Y. Y., Lowy, D. R., and Schiller, J. T. 2005. Maturation of papillomavirus capsids. J. Virol. 79, 2839-2846.
5. Chan, S. Y., Delius, H., Halpern, A. L., and Bernard, H. U. 1995. Analysis of genomic sequences of 95 papillomavirus types - Uniting typing, phylogeny, and taxonomy. J. Virol. 69, 3074-3083.
6. Chan, P. K., Li, W. H., Chan, M. Y., Ma, W. L., Cheung, J. L., and Cheng, A. F. 1999. High prevalence of human papillomavirus type 58 in Chinese women with cervical cancer and precancerous lesions. J. Med. Virol. 59, 232-238.
7. Clifford, G., Franceschi, S., Diaz, M., Munoz, N., and Villa, L. L. 2006. Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine24, S3/26-34.
8. Conway, M. J., Alam, S., Ryndock, E. J., Cruz, L., Christensen, N. D., Roden, R. B., and Meyers, C. 2009. Tissue-spanning redox gradient-dependent assembly of native human papillomavirus type 16 virions. J. Virol. 83, 10515-10526.
9. Conway, M. J. and Meyers, C. 2009. Replication and assembly of human papillomaviruses. J. Dent. Res. 88, 307-317.
10. Garland, S. M. and Smith, J. S. 2010. Human papillomavirus vaccines: current status and future prospects. Drugs70, 1079-1098.
11. Hara, H., Honda, A., Suzuki, H., Sata, T., and Matsukura, T. 2004. Detection of human papillomavirus type 58 in polydactylous Bowen's disease on the fingers and toes of a woman-concurrent occurrence of invasive vulval and cervical carcinomas. Dermatology209, 218-222.
12. Jiang, Z., Tong, G., Cai, B., Xu, Y., and Lou, J. 2011. Purification and immunogenicity study of human papillomavirus 58 virus-like particles expressed in Pichia pastoris. Protein Expr. Purif. 80, 203-210.
13. Kemp, T. J., Hildesheim, A., Safaeian, M., Dauner, J. G., Pan, Y., Porras, C., Schiller, J. T., Lowy, D. R., Herrero, R., and Pinto, L. A. 2011. HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection. Vaccine29, 2011-2014.
14. Kim, S. N., Jeong, H. S., Park, S. N., and Kim, H.-J. 2007. Purification and immunogenicity study of human papillomavirus type 16 L1 protein in Saccharomyces cerevisiae. J. Virol. Methods139, 24-30.
15. Kim, S. Y., Kim, H. J., and Kim, H.-J. 2011. Simple and convenient chromatography-based methods for purifying the pseudovirus of human papillomavirus type 58. Protein Expr. Purif. 76, 103-108.
16. Kim, H. J., Kim, S. Y., Lim, S. J., Kim, J. Y., Lee, S. J., and Kim, H.-J. 2010a. One-step chromatographic purification of human papillomavirus type 16 L1 protein from Saccharomyces cerevisiae. Protein Expr. Purif. 70, 68-74.
17. Kim, H. J., Lee, S. J., and Kim, H.-J. 2010b. Optimizing the secondary structure of human papillomavirus type 16 L1 mRNA enhances L1 protein expression in Saccharomyces cerevisiae. J. Biotechnol. 150, 31-36.
18. Kim, H. J., Lim, S. J., Kim, J. Y., Kim, S. Y., and Kim, H.-J. 2009. A method for removing contaminating protein during purification of human papillomavirus type 18 L1 protein from Saccharomyces cerevisiae. Arch. Pharm. Res. 32, 1759-1766.
19. Kim, H. J., Lim, S. J., and Kwag, H. L. 2012. The choice of resin-bound ligand affects the structure and immunogenicity of column-purified human papillomavirus type 16 virus-like particles. PLoS ONE7, e35893.
20. Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature227, 680-685.
21. Madrid-Marina, V., Torres-Poveda, K., Lopez-Toledo, G., and Garcia-Carranca, A. 2009. Advantages and disadvantages of current prophylactic vaccines against HPV. Arch. Med. Res. 40, 471-477.
22. Matsukura, T. and Sugase, M. 1990. Molecular cloning of a novel human papillomarvirus (type 58) from an invasive cervical carcinoma. Virology177, 833-836.
23. National Cancer Institute. 2007. Women's Health Report, Fiscal Years 2005-2006. NCI Women's Health Report FY2005-2006.
24. Nyari, T., Cseh, I., Woodward, M., Szollosi, J., Bak, M., and Deak, J. 2001. Screening for human papillomavirus infection in asymptomatic women in Hungary. Hum. Reprod. 16, 2235-2237.
25. Nyari, T. A., Kalmar, L., Deak, J., Szollosi, J., Farkas, I., and Kovacs, L. 2004. Prevalence and risk factors of human papilloma virus infection in asymptomatic women in southeastern Hungary. Eur. J. Obstet. Gynecol. Reprod. Biol. 115, 99-100.
26. Park, M. A., Kim, H. J., and Kim, H.-J. 2008. Optimum conditions for production and purification of human papillomavirus type 16 L1 protein from Saccharomyces cerevisiae. Protein Expr. Purif. 59, 175-181.
27. Pastrana, D. V., Buck, C. B., Pang, Y. Y., Thompson, C. D., Castle, P. E., FitzGerald, P. C., Kruger Kjaer, S., Lowy, D. R., and Schiller, J. T. 2004. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology321, 205-216.
28. Pattenden, L. K., Middelberg, A. P., Niebert, M., and Lipin, D. I. 2005. Towards the preparative and large-scale precision manufacture of virus-like particles. Trends Biotechnol. 23, 523-529.
29. Schadlich, L., Senger, T., Kirschning, C. J., Muller, M., and Gissmann, L. 2009. Refining HPV 16 L1 purification from E. coli: reducing endotoxin contaminations and their impact on immunogenicity. Vaccine27, 1511-1522.
30. Stockmann, C., Scheidle, M., Dittrich, B., Merckelbach, A., Hehmann, G., Melmer, G., Klee, D., Buchs, J., Kang, H. A., and Gellissen, G. 2009. Process development in Hansenula polymorpha and Arxula adeninivorans, a re-assessment. Microb. Cell Fact. 8, 22.
31. Sun, J., Song, X., and Hu, S. 2008. Ginsenoside Rg1 and aluminum hydroxide synergistically promote immune responses to ovalbumin in BALB/c mice. Clin. Vaccine Immunol. 15, 303-307.
32. Thones, N., Herreiner, A., Schadlich, L., Piuko, K., and Muller, M. 2008. A direct comparison of human papillomavirus type 16 L1 particles reveals a lower immunogenicity of capsomeres than viruslike particles with respect to the induced antibody response. J. Virol. 82, 5472-5485.
33. Vicente, T., Roldao, A., Peixoto, C., Carrondo, M. J., and Alves, P. M. 2011. Large-scale production and purification of VLP-based vaccines. J. Invertebr. Pathol. 107, S42-48.
34. Walboomers, J. M., Jacobs, M. V., Manos, M. M., Bosch, F. X., Kummer, J. A., Shah, K. V., Snijders, P. J., Peto, J., Meijer, C. J., and Munoz, N. 1999. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189, 12-19.
35. Wheeler, C. M., Castellsague, X., Garland, S. M., Szarewski, A., Paavonen, J., Naud, P., Salmeron, J., Chow, S. N., Apter, D., Kitchener, H., andet al. 2012. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 13, 100-110.
36. Woo, M. K., Hur, S. J., Park, S., and Kim, H.-J. 2007. Study of cell-mediated response in mice by HPV16 L1 virus-like particles expressed in Saccharomyces cerevisiae. J. Microbiol. Biotechnol. 17, 1738-1741.
37. Zhang, T., Xu, Y., Qiao, L., Wang, Y., Wu, X., Fan, D., Peng, Q., and Xu, X. 2010. Trivalent Human Papillomavirus (HPV) VLP vaccine covering HPV type 58 can elicit high level of humoral immunity but also induce immune interference among component types. Vaccine28, 3479-3487.